4.7 Article

Drimane Sesquiterpene Aldehydes Control Candida Yeast Isolated from Candidemia in Chilean Patients

Journal

Publisher

MDPI
DOI: 10.3390/ijms231911753

Keywords

drimane sesquiterpenoids; Drimys winteri; isotadeonal; winterdial; Candida yeast; lanosterol 14-alpha-demethylase; molecular dynamics

Funding

  1. ANID of the Chilean government under Fondecyt [1220831]
  2. CONICYT/Chile through the project Fondequip [EQM160054 2016]

Ask authors/readers for more resources

This study identified compounds from Drimys winteri (Winteraceae) that possess antifungal activity against Candida yeast. The most active compound, polygodial, showed fungistatic activity but caused irritation to the eyes and skin. A new compound, winterdial, was also discovered with potential antifungal properties. These findings are valuable for the development of more potent and safer drugs to treat candidiasis using natural compounds as a primary source.
Drimys winteri J.R. (Winteraceae) produce drimane sesquiterpenoids with activity against Candida yeast. In this work, drimenol, polygodial (1), isotadeonal (2), and a new drimane alpha,beta-unsaturated 1,4-dialdehyde, named winterdial (4), were purified from barks of D. winteri. The oxidation of drimenol produced the monoaldehyde drimenal (3). These four aldehyde sesquiterpenoids were evaluated against six Candida species isolated from candidemia patients in Chilean hospitals. Results showed that 1 displays fungistatic activity against all yeasts (3.75 to 15.0 mu g/mL), but irritant effects on eyes and skin, whereas its non-pungent epimer 2 has fungistatic and fungicide activities at 1.9 and 15.0 mu g/mL, respectively. On the other hand, compounds 3 and 4 were less active. Molecular dynamics simulations suggested that compounds 1-4 are capable of binding to the catalytic pocket of lanosterol 14-alpha demethylase with similar binding free energies, thus suggesting a potential mechanism of action through the inhibition of ergosterol synthesis. According to our findings, compound 2 appears as a valuable molecular scaffold to pursue the future development of more potent drugs against candidiasis with fewer side effects than polygodial. These outcomes are significant to broaden the alternatives to treat fungal infections with increasing prevalence worldwide using natural compounds as a primary source for active compounds.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available